44 completed, 7 recruiting, 4 active not recruiting, 4 terminated. 65 Phase 1, 15 Phase 2.
Follow Gallbladder Neoplasms: new trials by email Literature Review of Gallbladder Neoplasms trials Research Report on Gallbladder Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| IKS04 Regimen in Advanced Solid Tumors That Express CA242 IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody - Colorectal Cancer, Gastro Esophageal Junctional Cancer | Phase 1 | Not yet recruiting | Iksuda Therapeutics Ltd. | 120 | 2026-11-01 | 2026-07-31 |
| Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine - Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic | Phase 1 | Recruiting | Shanghai Zhongshan Hospital | 18 | 2026-05-01 | 2026-05-29 |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide - Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-06-11 |
| A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer Durvalumab or Pembrolizumab, Durvalumab or Pembrolizumab + Levnatinib, Durvalumab or Pembrolizumab + Venadaparib - Biliary Tract Neoplasms, Advanced Cancer | Phase 1 / Phase 2 | Not yet recruiting | Yonsei University | 160 | 2025-12-01 | 2025-12-08 |
| To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors XH001 Injection, mFOLFIRINOX Treatment Regimen - Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | Shenzhen Xinhe Biomedical | 48 | 2025-08-25 | 2026-05-19 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors MDX2001 - Biliary Tract Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 330 | 2024-06-12 | 2026-10-15 |
| Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases Cisplatin, Gemcitabine, Nab-paclitaxel - Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2022-09-19 | 2026-08-03 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 84 | 2022-04-13 | 2025-06-12 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors Felmetatug Vedotin, Pembrolizumab - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 250 | 2022-01-12 | 2026-01-09 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Atezolizumab, Tivozanib - Bile Duct Cancer, Gall Bladder Cancer | Phase 1 / Phase 2 | Recruiting | University of Florida | 29 | 2021-12-07 | 2026-07-13 |
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors ELI-002 2P - Minimal Residual Disease, KRAS G12D | Phase 1 | Completed | Elicio Therapeutics | 25 | 2021-10-04 | 2025-09-05 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 203 | 2021-03-14 | 2024-04-26 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Bevacizumab, Dasatinib, Fluorouracil - Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma | Phase 1 | Completed | Anne Noonan | 9 | 2020-09-02 | 2024-12-27 |
| Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) CPI 613, Gemcitabine, Cisplatin - Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 75 | 2020-06-23 | 2025-12-31 |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL) - Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms | Phase 1 / Phase 2 | Completed | Intima Bioscience, Inc. | 23 | 2020-05-15 | 2026-02-23 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 103 | 2020-04-07 | 2026-10-02 |
| Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor Andes-1537 for Injection - Tumor, Solid, Gall Bladder Cancer | Phase 1 | Completed | Andes Biotechnologies | 67 | 2019-04-26 | 2022-02-24 |
Showing 20 of 65. Sign in to see all of them.
Pancreatic Neoplasms (40) · Stomach Neoplasms (38) · Bile Duct Neoplasms (31) · Colonic Neoplasms (29) · Carcinoma, Hepatocellular (25) · Rectal Neoplasms (25) · Cholangiocarcinoma (23) · Esophageal Neoplasms (21) · Breast Neoplasms (18) · Carcinoma, Non-Small-Cell Lung (18) · Neoplasms (16) · Anus Neoplasms (15) · Endometrial Neoplasms (15) · Colorectal Neoplasms (14)
Biliary Tract Diseases (65) · Digestive System Diseases (65) · Digestive System Neoplasms (65) · Gallbladder Diseases (65) · Neoplasms by Site (65) · Biliary Tract Neoplasms (53) · Neoplasms by Histologic Type (53) · Neoplasms, Glandular and Epithelial (53) · Carcinoma (50) · Adenocarcinoma (49) · Neoplasms (49) · Endocrine Gland Neoplasms (47) · Endocrine System Diseases (47) · Gastrointestinal Diseases (43) · Gastrointestinal Neoplasms (41)
Gemcitabine (15) · Cisplatin (10) · Oxaliplatin (10) · Irinotecan (7) · Leucovorin (7) · Fluorouracil (6) · Capecitabine (4) · Cyclophosphamide (4) · Radiotherapy (4) · 1,2-diaminocyclohexaneplatinum II citrate (3) · 130-nm albumin-bound paclitaxel (3) · Albumin-Bound Paclitaxel (3) · Erlotinib Hydrochloride (3) · Interleukin-12 Subunit p35 (3) · Platinum (3)
National Cancer Institute (NCI) (7) · City of Hope Medical Center (3) · Memorial Sloan Kettering Cancer Center (3) · NYU Langone Health (2) · National Institutes of Health Clinical Center (CC) (2) · TransThera Sciences (Nanjing), Inc. (2) · University of Chicago (2) · University of Nebraska (2) · University of Southern California (2) · Abramson Cancer Center at Penn Medicine (1) · AccSalus Biosciences, Inc. (1) · Alliance for Clinical Trials in Oncology (1) · Andes Biotechnologies (1) · Andrew Lowy (1) · Anne Noonan (1)
United States (51) · China (5) · United Kingdom (4) · Germany (2) · South Korea (2) · Spain (2) · Australia (1) · Canada (1) · Chile (1) · France (1) · Italy (1) · Japan (1) · Singapore (1) · Sweden (1)
Franco M. Muggia, MD (2) · Herbert K. Lyerly, MD (2) · Jean L Grem, MD (2) · Anders Johnsson, MD, PhD (1) · Anne M Noonan, MBBChBAO, MSc (1) · Anthony El-Khoueiry (1) · Anthony El-Khoueiry, MD (1) · Anthony W. Tolcher, MD (1) · Bernadita Mendez, PhD (1) · Bert H. O'Neil, MD (1) · Daneng Li, MD (1) · Daniel H. Sterman, MD (1) · David R. Spriggs, MD (1) · Emil Lou, MD, PhD (1)
PMID 12196376, PMID 12393999, PMID 18470481, PMID 19023677, PMID 20068553, PMID 20179219, PMID 26912134, PMID 32878766, PMID 33142018, PMID 33210382, PMID 34499416, PMID 36399037, PMID 38195752, PMID 39263892, PMID 40315882, PMID 40543428, PMID 40673842, PMID 40790272, PMID 40932470, PMID 41495607, PMID 41740031
P30CA033572 (3), P30CA014089 (2), P30CA016087 (2), P30CA036727 (2), P30CA068485 (2), 2015 (1), 2023 (1), 2025 (1), P30CA013330 (1), P30CA014599 (1), P30CA015083 (1), P30CA016086 (1), P30CA016672 (1), P30CA043703 (1), P30CA044579 (1)